204 related articles for article (PubMed ID: 8574470)
1. Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor.
Ossevoort MA; Feltkamp MC; van Veen KJ; Melief CJ; Kast WM
J Immunother Emphasis Tumor Immunol; 1995 Aug; 18(2):86-94. PubMed ID: 8574470
[TBL] [Abstract][Full Text] [Related]
2. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides.
Zwaveling S; Ferreira Mota SC; Nouta J; Johnson M; Lipford GB; Offringa R; van der Burg SH; Melief CJ
J Immunol; 2002 Jul; 169(1):350-8. PubMed ID: 12077264
[TBL] [Abstract][Full Text] [Related]
3. Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway.
Peng S; Frazer IH; Fernando GJ; Zhou J
Virology; 1998 Jan; 240(1):147-57. PubMed ID: 9448699
[TBL] [Abstract][Full Text] [Related]
4. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells.
Feltkamp MC; Smits HL; Vierboom MP; Minnaar RP; de Jongh BM; Drijfhout JW; ter Schegget J; Melief CJ; Kast WM
Eur J Immunol; 1993 Sep; 23(9):2242-9. PubMed ID: 7690326
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic-T-lymphocyte human papillomavirus type 16 E5 peptide with CpG-oligodeoxynucleotide can eliminate tumor growth in C57BL/6 mice.
Chen YF; Lin CW; Tsao YP; Chen SL
J Virol; 2004 Feb; 78(3):1333-43. PubMed ID: 14722288
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of dendritic cell-based HPV16 E6/E7 peptide vaccines: CTL activation and protective effects.
Indrová M; Reinis M; Bubeník J; Jandlová T; Bieblová J; Vonka V; Velek J
Folia Biol (Praha); 2004; 50(6):184-93. PubMed ID: 15709713
[TBL] [Abstract][Full Text] [Related]
7. A vaccine conjugate of 'ISCAR' immunocarrier and peptide epitopes of the E7 cervical cancer-associated protein of human papillomavirus type 16 elicits specific Th1- and Th2-type responses in immunized mice in the absence of oil-based adjuvants.
Tindle RW; Croft S; Herd K; Malcolm K; Geczy AF; Stewart T; Fernando GJ
Clin Exp Immunol; 1995 Aug; 101(2):265-71. PubMed ID: 7544248
[TBL] [Abstract][Full Text] [Related]
8. Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells.
De Bruijn ML; Schuurhuis DH; Vierboom MP; Vermeulen H; de Cock KA; Ooms ME; Ressing ME; Toebes M; Franken KL; Drijfhout JW; Ottenhoff TH; Offringa R; Melief CJ
Cancer Res; 1998 Feb; 58(4):724-31. PubMed ID: 9485027
[TBL] [Abstract][Full Text] [Related]
9. Mapping of cytotoxic T lymphocytes epitopes in E7 antigen of human papillomavirus type 11.
Xu Y; Zhu KJ; Chen XZ; Zhao KJ; Lu ZM; Cheng H
Arch Dermatol Res; 2008 Jun; 300(5):235-42. PubMed ID: 18299861
[TBL] [Abstract][Full Text] [Related]
10. Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer.
Liu DW; Tsao YP; Kung JT; Ding YA; Sytwu HK; Xiao X; Chen SL
J Virol; 2000 Mar; 74(6):2888-94. PubMed ID: 10684306
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice.
Ohlschläger P; Osen W; Dell K; Faath S; Garcea RL; Jochmus I; Müller M; Pawlita M; Schäfer K; Sehr P; Staib C; Sutter G; Gissmann L
J Virol; 2003 Apr; 77(8):4635-45. PubMed ID: 12663770
[TBL] [Abstract][Full Text] [Related]
12. A DNA vaccine based on a shuffled E7 oncogene of the human papillomavirus type 16 (HPV 16) induces E7-specific cytotoxic T cells but lacks transforming activity.
Osen W; Peiler T; Ohlschläger P; Caldeira S; Faath S; Michel N; Müller M; Tommasino M; Jochmus I; Gissmann L
Vaccine; 2001 Jul; 19(30):4276-86. PubMed ID: 11457555
[TBL] [Abstract][Full Text] [Related]
13. Peptide vaccination with an anchor-replaced CTL epitope protects against human papillomavirus type 16-induced tumors expressing the wild-type epitope.
Vierboom MP; Feltkamp MC; Neisig A; Drijfhout JW; ter Schegget J; Neefjes JJ; Melief CJ; Kast WM
J Immunother; 1998 Nov; 21(6):399-408. PubMed ID: 9807734
[TBL] [Abstract][Full Text] [Related]
14. Immunization against human papillomavirus infection and associated neoplasia.
Osen W; Jochmus I; Müller M; Gissmann L
J Clin Virol; 2000 Oct; 19(1-2):75-8. PubMed ID: 11091150
[TBL] [Abstract][Full Text] [Related]
15. Therapy of HPV 16-associated carcinoma with dendritic cell-based vaccines: in vitro priming of the effector cell responses by DC pulsed with tumour lysates and synthetic RAHYNIVTF peptide.
Indrová M; Bubeník J; Símová J; Vonka V; Nemecková S; Mendoza L; Reinis M
Int J Mol Med; 2001 Jan; 7(1):97-100. PubMed ID: 11115616
[TBL] [Abstract][Full Text] [Related]
16. Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: induction of cytotoxic T cells and specific tumor protection.
Schäfer K; Müller M; Faath S; Henn A; Osen W; Zentgraf H; Benner A; Gissmann L; Jochmus I
Int J Cancer; 1999 Jun; 81(6):881-8. PubMed ID: 10362134
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cell-based tumor vaccine for cervical cancer I: in vitro stimulation with recombinant protein-pulsed dendritic cells induces specific T cells to HPV16 E7 or HPV18 E7.
Nonn M; Schinz M; Zumbach K; Pawlita M; Schneider A; Dürst M; Kaufmann AM
J Cancer Res Clin Oncol; 2003 Sep; 129(9):511-20. PubMed ID: 12905010
[TBL] [Abstract][Full Text] [Related]
18. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16.
Gunn GR; Zubair A; Peters C; Pan ZK; Wu TC; Paterson Y
J Immunol; 2001 Dec; 167(11):6471-9. PubMed ID: 11714814
[TBL] [Abstract][Full Text] [Related]
19. Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion.
Daftarian P; Mansour M; Benoit AC; Pohajdak B; Hoskin DW; Brown RG; Kast WM
Vaccine; 2006 Jun; 24(24):5235-44. PubMed ID: 16675074
[TBL] [Abstract][Full Text] [Related]
20. Limitations of HLA-transgenic mice in presentation of HLA-restricted cytotoxic T-cell epitopes from endogenously processed human papillomavirus type 16 E7 protein.
Street MD; Doan T; Herd KA; Tindle RW
Immunology; 2002 Aug; 106(4):526-36. PubMed ID: 12153516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]